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Abstract
Aims/hypothesis We assessed whether per-arnt-sim (PAS)
domain-containing protein kinase (PASK) is involved in the
regulation of glucagon secretion.
Methods mRNA levels were measured in islets by quanti-
tative PCR and in pancreatic beta cells obtained by laser
capture microdissection. Glucose tolerance, plasma hor-
mone levels and islet hormone secretion were analysed in
C57BL/6 Pask homozygote knockout mice (Pask−/−) and
control littermates. Alpha-TC1-9 cells, human islets or
cultured E13.5 rat pancreatic epithelia were transduced with
anti-Pask or control small interfering RNAs, or with
adenoviruses encoding enhanced green fluorescent protein
or PASK.
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Results PASK expression was significantly lower in islets
from human type 2 diabetic than control participants. PASK
mRNA was present in alpha and beta cells from mouse
islets. In Pask−/− mice, fasted blood glucose and plasma
glucagon levels were 25±5% and 50±8% (mean ± SE)
higher, respectively, than in control mice. At inhibitory
glucose concentrations (10 mmol/l), islets from Pask−/−
mice secreted 2.04±0.2-fold (p<0.01) more glucagon and
2.63±0.3-fold (p<0.01) less insulin than wild-type islets.
Glucose failed to inhibit glucagon secretion from PASK-
depleted alpha-TC1-9 cells, whereas PASK overexpression
inhibited glucagon secretion from these cells and human
islets. Extracellular insulin (20 nmol/l) inhibited glucagon
secretion from control and PASK-deficient alpha-TC1-9
cells. PASK-depleted alpha-TC1-9 cells and pancreatic
embryonic explants displayed increased expression of the
preproglucagon (Gcg) and AMP-activated protein kinase
(AMPK)-alpha2 (Prkaa2) genes, implying a possible role
for AMPK-alpha2 downstream of PASK in the control of
glucagon gene expression and release.
Conclusions/interpretation PASK is involved in the regu-
lation of glucagon secretion by glucose and may be a useful
target for the treatment of type 2 diabetes.
Keywords Αlpha cells . Glucagon secretion . Human islets
of Langerhans . Knockout mouse . PASK
Abbreviations
AMPK AMP-activated protein kinase
PAS Per-arnt-sim
PASK PAS domain-containing protein kinase
Pask−/− Pask homozygote knockout mice
siRNA Small interfering RNA
Introduction
Elevated glucose concentrations (>3.5 mmol/l) normally
suppress the release of glucagon from pancreatic alpha
cells; dysregulation of this process is a feature of type 1 and
type 2 diabetes [1, 2]. Both direct [3] and indirect [4]
effects of glucose on the release of glucagon have been
described. Whereas the latter appear to involve the release
of secretory products, including insulin [3, 5], gamma-
aminobutyric acid [6–8] or zinc ions [4, 9] from neighbour-
ing beta cells, as well as somatostatin from delta cells
[10, 11], the signalling events involved in the direct sensing
of glucose are more controversial [12]. These may involve
enhanced metabolism of glucose and the closure of ATP-
sensitive K+ channels, followed by limited membrane
depolarisation [13, 14]. AMP-activated protein kinase
(AMPK) appears also to be involved in the regulation of
glucagon release [15].
Per-arnt-sim (PAS) domain-containing protein kinases
(PASKs) are related to AMPK and are common in
prokaryotes. However, there is currently only one known
mammalian counterpart [16, 17]. We [18] and others [19, 20]
have shown that PASK is important for energy sensing and
maintenance of normal cellular energy balance in mamma-
lian systems.
In pancreatic beta cells, PASK activity is regulated by
glucose and is involved in the regulation of glucose-induced
preproinsulin and pancreatic duodenum homeobox-1 (Pdx1)
gene expression [18, 20]. Expression of the Pask gene in
rodent islets and beta cell lines [18, 20] is also glucose-
sensitive. Recently, PASK has been implicated in regulation
of lipogenic gene expression [19] and might, therefore,
influence glucose signalling through lipid intermediates as
proposed for glucose-induced insulin secretion [21].
Pask homozygote knockout mice (Pask−/−), which are
globally inactivated for Pask, have previously been
reported to display lower plasma insulin levels than control
littermates [19], but normal glucose tolerance [19, 22],
reflecting enhanced insulin sensitivity [19]. Insulin secre-
tion from Pask−/− islets has variously been shown to be not
different [22] or lower [19] than in control islets. It has also
been previously reported that total insulin content and/or
beta cell mass were not altered in Pask−/− mice [19, 22].
However, data from these earlier studies are difficult to
interpret for a number of reasons. In the first instance, total
islet insulin was not always measured, making it difficult to
evaluate the insulin secretory capacity of Pask−/− islets.
Moreover quantification of beta cell mass using pancreatic
sections is prone to substantial variability [19]. Due to these
limitations [19, 22], the role of PASK in the regulation of
pancreatic hormone release and glucose homeostasis
remains to be clarified.
A recent report [20] showed that inhibition of insulin gene
expression by palmitate was reversed by Pask overexpres-
sion in MIN6 beta cells. The loss of PASK, and hence the
loss of regulation by Pdx1 and Mafa gene expression [18],
was proposed to be a mechanism by which insulin gene
expression in the beta cell might be lost on exposure to
palmitate [20]. Thus, PASK appears to exert a protective
effect in mature beta cells. Moreover, aberrant PASK
expression and/or function may play a significant role in
the development of diabetes and, interestingly, Pask−/− mice
develop glucose intolerance on a high-fat diet [18].
Although glucose homeostasis reflects the release of
multiple islet hormones in addition to insulin, there are
currently no published data on the role of PASK in other
islet cell types. The present study demonstrates that PASK
is involved in the regulation of glucagon secretion from
pancreatic alpha cells. We show that PASK expression is
decreased in the islets of human type 2 diabetic patients and
that Pask is at least as strongly expressed in highly purified
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mouse alpha cells as in beta cells. Silencing or ablation of
Pask in clonal alpha cells or islets, respectively, drastically
blunted the inhibition of glucagon secretion by glucose.
Whereas the insulin content of PASK-deficient islets was
dramatically reduced, the acute regulation of insulin
secretion by glucose was normal. Thus, PASK regulates
hormone release reciprocally from pancreatic alpha and
beta cells. Given that dysregulation of insulin and glucagon
secretion are characteristics of type 2 diabetes, we propose
that PASK may be a potential drug target to modulate
glucagon release in vivo.
Methods
Materials Adenoviruses encoding for human PASK have
been previously described [16]. All general chemicals and
tissue culture reagents were purchased from Sigma (Poole,
UK) or Invitrogen (Paisley, UK), unless otherwise stated in
the text.
Isolation and culture of islets Studies on human islets were
conducted with local ethics committee approval at all sites
(Charing Cross Research Ethics Committee Ref. 07/H0711/
114). Human islets were isolated as previously de-
scribed in Oxford, UK [23], or in Pisa, Italy [24], and
maintained in medium containing 11 mmol/l glucose for
10 days to allow the loss of exocrine tissue [25]. Human
type 2 diabetic donors were selected according to
established criteria [23, 26]. Mouse pancreatic islets were
isolated and cultured as described in [3]. Alpha-TC1-9
cells (passage 35–45; American Type Culture Collection,
Manassas, VA, USA) were cultured as previously
described [7].
Laser capture microdissection and microarray analysis These
procedures were performed as described in Electronic
supplementary material (ESM) Methods.
RNA sequencing We prepared 300 ng of total RNA with a
kit (mRNA-Seq 8; Illumina, Little Chesterford, UK). For
clustering and sequencing we used Illumina cluster gener-
ation and sequencing kits v4. 9pM were loaded to the
flowcell (one sample per lane) and sequenced on a
sequencer (GAIIx) with RTA software version 2.6 (Little
Chesterford, UK). On average we obtained 28 million reads
per lane, passing Illumina’s quality filtering. Short reads
(35 bp) were aligned to the mouse genome (Ensembl v54)
using a mapping station (Genomatix) [27] and to a database
of known and potential splice junctions using Bowtie [28].
Up to three mismatches and no insertions or deletions were
allowed, and, on average, more than 85% of the reads in a
sample could be mapped to the genome. Gene expression
was measured as proposed by Mortazavi et al. [29] and
reads per kilobase per million (RPKM) values were
computed for every gene.
Mice Pask−/− mice (kindly provided by R. Wenger, Institute
of Physiology and ZIHP, Zurich, Switzerland) [30] were
back-crossed for ten generations with C57BL/6 mice prior
to use. Mice were housed with two to five animals per cage
in a pathogen-free facility on a 12 h light–dark cycle with
free access to standard mouse chow diet, unless otherwise
stated. All in vivo procedures were performed in the
Imperial College Central Biomedical Service in accordance
with the Principles of Laboratory Care and the UK Home
Office (Animals Scientific Procedures Act, 1986), and
approved by the local ethics committee. Genotyping was
performed as previously described [30].
Intraperitoneal glucose tolerance test An intraperitoneal
glucose tolerance test was performed on 8-week-old mice as
described in [31], at 09:00 hours on each experimental day.
Measurement of total pancreatic insulin and glucagon Pan-
creases were excised from 8-week-old mice and suspended
in ice-cold acid–ethanol (75.0% ethanol–23.4% molecular
grade water–1.5% HCl–0.1% Triton X-100, vol./vol.) prior
to disruption by sonication (microsonicator; Misonix, Farm-
ingdale, NY, USA) at 4°C. Total protein was measured by
Bradford’s assay [32], and insulin and glucagon content were
measured by radioimmunoassay (Linco, Watford, UK).
Measurement of plasma glucagon At 8 weeks of age mice
were starved overnight prior to being killed by cervical
dislocation. Blood (200 μl) was immediately removed by
cardiac puncture. Plasma was collected using high-speed
centrifugation (2,000 g, 5 min) in heparin-coated tubes
(Microvette; Sarstedt, Leicester, UK) and plasma glucagon
assessed by radioimmunoassay (Linco, Watford, UK).
Manipulation of PASK content in alpha-TC1-9 cells and
cultured islets of Langerhans Alpha-TC1-9 cells and islets
were infected with adenoviruses encoding for PASK or
enhanced green fluorescent protein at a multiplicity of
infection of 100 and cultured for 48 h prior to use. Alpha-
TC1-9 cells were transfected with anti-Pask small interfering
RNA (siRNA) or control siRNA (1 nmol/l) [18]. Protein
content was assessed by western (immuno-)blot analysis.
Culture of E13.5 rat pancreatic epithelia E13.5 rat pancre-
atic epithelia were isolated and cultured as previously
described [33]. Epithelia were cultured in the presence of
anti-Pask siRNA or control siRNA [18] (1 nmol/l) for
10 days prior to RNA isolation for real-time quantitative
PCR analysis.
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Real-time quantitative PCR analysis Highly purified pri-
mary mouse islet beta and alpha cells were obtained by
fluorescence-activated cell sorting of transgenic mice
expressing the fluorescent protein Venus selectively in the
alpha cell under the preproglucagon promoter [34, 35].
RNAwas extracted from alpha-TC1-9 cells and cultured rat
E13.5 explants using Trizol (Invitrogen) according to the
manufacturer’s guidelines. Total RNA was subjected to
DNAse treatment (Ambion, Warrington, UK), followed by
cDNA conversion (high-capacity cDNA conversion kit;
Applied Biosystems, Warrington, UK) and real-time quan-
titative PCR using SYBR green (Applied Biosystems) in a
7500 Real-Time PCR System (ABI, Warrington, UK).
Western (immuno-)blot analysis Western (immuno-)blot
analysis was performed as previously described [18].
Statistical analysis Data are the means ± SE for the number
of observations indicated. Statistical significance and
differences between means were assessed by Student’s t
test with Bonferroni correction for multiple analyses.
Results
PASK gene expression is regulated by glucose in human
pancreatic islets of Langerhans and is lowered in type 2
diabetes We have previously shown that Pask mRNA and
protein levels are increased by high glucose in rat islets and
clonal MIN6 beta cells [18]. Here, we first determined
whether islet PASK expression may also be regulated by
glucose or by diabetes in humans. Measured in human
islets of Langerhans by quantitative PCR, PASK mRNAwas
elevated after 24 h culture at 11 mmol/l glucose (2.7±0.2-
fold vs culture at 3 mmol/l glucose [means ± SE]; Fig. 1a).
Measured after culture at 11 mmol/l glucose, PASK gene
expression was significantly lower in islets from patients
with type 2 diabetes than in control islets (Fig. 1b).
mRNA expression data obtained using whole islets may be
confounded by variable degrees of contamination with
other pancreatic cell types, as well as by other factors.
Therefore, we sought to further support the above results by
using laser capture microdissection and array analysis to
quantify mRNA levels selectively in beta cell-enriched
samples [26]. A clear tendency for decreased PASK
expression in islets in type 2 diabetic pancreases vs controls
was also observed using this approach (ESM Fig. 1). In
contrast, consistent changes in levels of the AMPK-alpha1
and -alpha2 subunit (encoded by PRKAA1 and PRKAA2,
respectively) were not observed with array data on samples
obtained by laser capture microdissection. However, with
quantitative PCR done on the same samples with enough
RNA (10 vs 10), a small but statistically significant
decrease in PRKAA1 expression was apparent (18%; p<
0.019), using RPL32 as an internal control.
Pask is expressed in murine pancreatic beta and alpha
cells In the mouse, Pask mRNA has previously been
shown to be most abundant in testes as well as in
haemopoietic tissues including thymus and spleen [30].
Levels in other tissues, including islets, are much lower
[30] (G. A. Rutter and G. Sun, unpublished observations).
Indeed, the expression of Pask in adult mouse islets and its
induction by glucose have recently been questioned, since
expression in these cells of the lacZ gene, expressed in mice
null for Pask alleles under the Pask promoter, was barely
detectable by beta-Gal staining [22]. By contrast, we have
previously detected Pask mRNA in mouse islets and MIN6
cells [18], data recently confirmed by others [20]. Exam-
ined here in islets from mice on a mixed C57BL/6/sv129
background cultured at 11 mmol/l glucose, massive parallel
sequencing (RNAseq) confirmed the presence of Pask
mRNA at low but detectable levels, lying in the lower
30th percentile of all mRNAs at approximately 0.2±0.3%
(n=3 female mice) of β-actin mRNA levels (ESM Fig. 2).
To determine in which cell types Pask was expressed in
mouse islets, we next compared the expression of Pask
mRNA in highly purified primary mouse alpha and beta
cells (Fig. 1c). These were obtained by fluorescence-
activated cell sorting of transgenic mice selectively express-
ing the fluorescent protein, Venus, in the alpha cell [34, 35]
and by real-time quantitative PCR analysis. This approach
confirmed the presence of Pask mRNA in both cell types
and indicated that levels in purified alpha cells (1.45±
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Fig. 1 PASK expression is regulated by glucose in human islets and is
lowered in type 2 diabetic islets. Real-time quantitative PCR on non-
diabetic (a, b) or type 2 diabetic (T2D) (b) human islet RNA,
following culture at the indicated glucose concentrations for 24 h (a)
or at 11 mmol/l glucose (b); n=3; *p<0.05, **p<0.01. c Pask mRNA
content in FACS-purified mouse alpha and beta cells; †p=0.07
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0.46% of beta-actin mRNA) tended to be higher than in
beta cells (0.54±0.044%; n=3 preparations; p=0.07 by
two-tailed Student’s t test).
Pask−/− mice display normal glucose tolerance but im-
paired plasma glucagon concentration Given the greater
expression of Pask in alpha than in beta cells and the
dysregulation of glucagon secretion observed in type 2
diabetes, as reviewed by others [2], we next analysed the
potential contribution of this enzyme to the regulation of
glucagon secretion using Pask−/− mice. At 8 weeks of age,
Pask−/− male (Fig. 2a, c, e) and female (Fig. 2b, d) mice
displayed 25±5% higher plasma glucose levels after 16 h
of fasting than wild-type littermate control mice, but normal
glucose tolerance after intraperitoneal injection of the sugar
(Fig. 2a–d). Measured after fasting, plasma glucagon was
significantly higher in Pask−/− male mice than in littermate
controls (91±5.4 vs 58±3 pg/ml; Fig. 2e).
Islets of Langerhans from Pask−/− mice display impaired
glucose-regulated glucagon secretion We next examined
whether the elevated plasma glucagon concentration was
due to dysregulation of alpha cell function. Supporting this
view, the inhibition of glucagon secretion in response to
elevated glucose was impaired in islets from Pask−/− mice
(Fig. 3a). Thus, Pask−/− islets, in which Pask gene
expression was undetectable (Fig. 3e), secreted 2.04±0.2-
fold more glucagon at inhibitory (10 mmol/l) glucose
concentrations than did islets from wild-type littermates
(Fig. 3a), whereas release at stimulatory (0.5 mmol/l)
glucose was unaltered. Interestingly, a slight inhibitory
effect on glucagon secretion in Pask−/− islets was still
observed at 10 mmol/l glucose (Fig. 3a). Although glucose-
stimulated insulin release when normalised to total islet
insulin content was not affected by Pask deletion (Fig. 3b),
the total amount of insulin per islet was lower (0.38±0.3-
fold) in Pask−/− than in wild-type islets (Fig. 3d), i.e. the
amount of insulin release was compromised in Pask−/−
islets, in agreement with published data [19].
The expression of mouse preproinsulin 2 (Ins2) and
Pdx1 genes was strongly impaired in Pask−/− mouse islets
(Fig. 3e), as previously reported [18, 20]. Moreover, the
ba
dc
e
0.0
0.4
0.8
1.2
G
lu
ca
go
n 
se
cr
et
io
n 
(%
 se
cre
ted
 /to
tal
)
G
lu
ca
go
n 
co
nt
en
t 
(ng
 /1
0 i
sle
ts)
0
4
8
12
16
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.4
0.8
1.2
**
** ** *
** *
**
*
**
In
su
lin
 se
cr
et
io
n 
(%
 se
cre
ted
 /to
tal
)
In
su
lin
 c
on
te
nt
 
(m
g /
10
 is
let
s)
Pask+/+ Pask+/− Pask−/− Pask+/+ Pask+/− Pask−/−
Pask+/+ Pask+/− Pask−/− Pask+/+ Pask+/− Pask−/−
G
en
e 
ex
pr
es
sio
n 
(no
rm
ali
sed
 to
 co
ntr
ol)
0.0
0.4
0.8
1.2
nd
Pask Ins2 Gcg Pdx1
** ** ***
** **
Prkaa2
*
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glucagon secretion in response to glucose. a Glucagon and (b) insulin
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Fig. 2 Pask−/− mice display higher fasted glucose levels than
littermate controls. At 8 weeks of age, male (a, c) and female (b, d)
Pask−/− mice were starved for 16 h prior to an intraperitoneal glucose
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insulin content of whole Pask−/− mouse pancreases was
1.98±0.3-fold lower than that of wild-type pancreases (67±
15 vs 133±12 ng/mg protein for Pask−/− and wild-type
mice, respectively; n=3 mice for each genotype). While
glucagon protein content in Pask−/− islets (Fig. 3c) was
unaffected, preproglucagon (Gcg) gene expression was
slightly but significantly increased, as was Prkaa2 mRNA
expression (Fig. 3e).
Glucagon release is activated in the absence of Pask in
alpha-TC1-9 cells Since the above experiments using intact
islets did not allow ready discrimination between an action
of PASK cell-autonomously in the alpha cell and an effect
mediated by changes in the release of beta cell-derived
factors, we next explored the role of the enzyme in the
clonal alpha-TC1-9 cell line [3]. Culture of alpha-TC1-9
cells in the presence of an siRNA against Pask led to near
complete ablation of Pask gene expression and protein
content (Fig. 4a). Glucagon release from Pask-deficient
alpha-TC1-9 cells at inhibitory (10 mmol/l) glucose con-
centrations was comparable to that observed in control cells at
stimulatory (0.5 mmol/l) glucose concentrations (Fig. 4b). By
contrast, addition of extracellular insulin (20 nmol/l) led to
inhibition of glucagon secretion in control and Pask-silenced
alpha-TC1-9 cells, indicating (1) the presence of distinct
glucose and insulin signalling pathways in the alpha cell and
(2) that the insulin signalling pathway in Pask-silenced
alpha-TC1-9 cells was intact (Fig. 4b). Total glucagon
protein content, as assessed by radioimmunoassay, was not
different between alpha-TC1-9 cells treated with control or
anti-Pask siRNA (data not shown).
Glucagon release is inhibited by PASK overexpression in
alpha-TC1-9 cells and human islets of Langerhans The
above findings indicated that PASK may be an inhibitor of
glucagon release from alpha cells. To test this hypothesis,
we next explored the impact of forced activation of the
enzyme in these cells. Adenovirus-mediated overexpression
of PASK in alpha-TC1-9 cells (Fig. 5a) led to inhibition of
glucagon secretion at normally stimulatory (1 mmol/l)
glucose concentrations (0.36±0.1-fold vs control).
Similarly, overexpression of PASK in human islets of
Langerhans (Fig. 5b) inhibited glucagon secretion at all
glucose concentrations tested, while the stimulatory effects
of KCl were largely maintained. Interestingly, there was
still an apparent effect of glucose on glucagon secretion in
human islets overexpressing PASK (Fig. 5b), consistent
with a maintained effect on glucagon release mediated by
beta cell-derived factors.
Silencing of Pask gene expression in alpha-TC1-9 cells and
E13.5 rat pancreatic epithelial explants causes increased
AMPK-alpha2 and glucagon gene expression In an effort
to identify the mechanism(s) through which PASK may
regulate glucagon secretion, we measured the expression of
a number of potential target genes. Pask gene expression
was inhibited in alpha-TC1-9 cells treated with a siRNA
against Pask (Fig. 6). In line with the above findings in
Pask−/− mouse islets (Fig. 3e), preproglucagon (Gcg) gene
expression was increased substantially by Pask ablation in
alpha-TC1-9 cells (7.4±1.3-fold vs control; Fig. 6a),
although total glucagon protein content was unaltered
(Fig. 2c), consistent with the relatively slow turnover of
mature glucagon. Prkaa2 (Fig. 6a), but not Prkaa1 (data
not shown) gene expression was also increased (4.3±1.5-
fold vs control) by Pask silencing.
To determine whether the dysregulation of glucagon gene
expression and release inPask−/− mice was due to a role of the
enzyme in the development of pancreatic alpha and beta cells,
we next examined the impact of Pask silencing in developing
pancreatic epithelia. E13.5 rat pancreatic epithelial explants
[33], in which Pask gene expression was silenced with an
anti-Pask siRNA, developed endocrine buds to an extent
indistinguishable from that observed in explants treated with a
control (scrambled) siRNA (ESM Fig. 3). However, explants
in which Pask was silenced displayed similar increases in Gcg
and Prkaa2 gene expression (ESM Fig. 3) to those observed
in alpha-TC1-9 cells (Fig. 6). Explants overexpressing Pask
did not survive the 10 day culture period.
Discussion
The present data indicate that PASK/Pask is expressed in
human and mouse pancreatic islets, respectively, and
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regulated by glucose. Moreover, in the mouse, Pask mRNA
levels are at least as high in alpha cells as in beta cells.
Correspondingly, we provide evidence that changes in Pask
gene expression within the islet regulate both insulin
content [18, 20] and glucagon release, i.e. that PASK
mediates a ‘high glucose’ signal in alpha and beta cells. In
the alpha cell, this might be achieved either via a cell-
autonomous action on cellular activity and/or through
changes in the release of beta cell-derived factors (Fig. 7).
Either of these mechanisms are likely to modulate intracel-
lular signalling within the alpha cell through changes in
membrane excitability, levels of unbound Ca2+, cAMP, etc.
PASK is expressed in pancreatic islets An important
finding of the present study is that Pask mRNA is clearly
present in mouse islets maintained at permissive glucose
concentrations (11 mmol/l), in contrast to a recent sugges-
tion [22]. These results and those from another recent
publication [20] support our own previous findings [18].
We would stress, however, that the level of gene expres-
sion, at least at the mRNA level, was relatively low
compared with tissues in which Pask is strongly expressed
(notably in the testes) [22], an observation that probably
underlies the failure to detect significant expression using
alternative approaches [22].
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AMPK-alpha2
PASK
AMPK-
alpha2
Glucose Glucose
Alpha cell
Insulin, other 
factors Glucagon
Insulin, other 
receptors
(1)
(2)
(3)
Beta cell
Nucleus
Fig. 7 Proposed mechanism for PASK action in alpha cells. Glucagon
secretion is regulated by changes in extracellular glucose and other
factors, including insulin and possibly other molecules released from
pancreatic beta cells. We propose (dashed lines) that PASK may be
involved in cell-autonomous regulation of glucagon secretion,
possibly through the regulation of Prkaa2 gene expression (AMPK-
alpha2) (1) and/or an as yet unidentified pathway (2). PASK may also
regulate glucagon secretion through its action on beta cell function
and/or beta cell mass (3)
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Fig. 5 Overexpression of PASK inhibits glucagon secretion in alpha-
TC1-9 cells and human islets of Langerhans. a Alpha-TC1-9 cells
were infected with adenovirus encoding for PASK (grey bars) or
enhanced green fluorescent protein (EGFP; control virus, white bars)
at multiplicity of infection of 100 and cultured for 24 h prior to
glucagon secretion as described in Fig. 3, n=3. b Human islets of
Langerhans were infected with adenovirus for human PASK or EGFP
at multiplicity of infection of 100 and cultured for 48 h prior to
glucagon secretion assay [3], n=3. Data presented are % secreted
hormone/total hormone content per sample. c Western (immuno-)blot
analysis of protein extracts from alpha-TC1-9 cells and human pancreatic
islets after 48 h transduction with adenoviruses encoding for PASK or
EGFP. PASK protein content was normalised to tubulin protein content as
assessed by densitometry using ImageJ (http://rsbweb.nih.gov/ij/index.
html; n=3). Representative images from at least three separate
preparations of each are shown. *p<0.05, **p<0.01
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PASK regulates insulin and glucagon secretion It has
previously been shown that islet architecture and beta cell
mass in Pask−/− mice are intact [19, 22]. Thus, it was
hypothesised in earlier studies that the observed decrease in
insulin release may have been due to defective glucose-
signalling in the beta cell [19]. In contrast, our data show
that glucose-regulated insulin secretion was intact in Pask−/−
islets (Fig. 3b), but that the insulin content of the islet
(Fig. 3d) and pancreas (see Results section) were lowered by
Pask deletion. This apparent discrepancy between the present
and earlier [19, 22] studies may reflect differences in the
genetic background, age and sex of the mice used. We
would, however, note that Pask−/− beta cell mass was
previously assessed by immunohistochemical analysis of
fixed pancreatic sections, which may be prone to error.
Nevertheless, it was previously reported that plasma
insulin content was compromised in Pask−/− mice [19], a
result consistent with the present findings. In our hands,
glucagon release from Pask−/− mouse islets (Fig. 3a) and
human islets in which PASK was overexpressed (Fig. 5b)
still displayed some degree of glucose-responsiveness, even
though this was markedly decreased compared with the
control condition. We hypothesise that this ‘residual’ regula-
tion of release may be due, at least in part, to the release of
insulin or other factors (Zn2+, gamma-aminobutyric acid,
etc.) from neighbouring pancreatic beta cells and is
consistent with the maintained effect of exogenous insulin
on glucagon release from alpha-TC1-9 cells (Fig. 4b).
Close inspection of the data of Fig. 3a vs Fig. 4 reveals
that whereas loss of Pask enhanced glucagon secretion
from islets only at high (inhibitory) glucose levels (Fig. 3a),
stimulation of glucagon release was apparent at all glucose
concentrations examined in alpha-TC1-9 cells (Fig. 4). The
mechanisms responsible for this difference are unclear.
However, we note that while insulin mRNA was present at
low but detectable levels in control alpha-TC-1-9 cells
(Ct values ≥29; data not shown), silencing of Pask led to
decreased insulin gene expression such that this was below
the limit of detection. Hence an action of Pask silencing on
endogenous insulin secretion from alpha-TC-1-9 cells, and
thus loss of tonic inhibition of glucagon secretion by this
hormone, may contribute to the above mechanisms. Further
studies are needed to resolve this question.
Interestingly, the increase in plasma glucagon levels
measured after 16 h fasting in 8-week-old Pask−/− mice was
similar to that observed in alpha cell-specific insulin
receptor knockout mice of the same age [5]. We have
previously shown that PASK activity is not regulated by
insulin, but that PASK may regulate insulin gene expression
in pancreatic beta cells [18]. Thus, we propose that the
regulation of insulin content by Pask is one of the
mechanisms through which PASK may indirectly regulate
glucagon release.
A role for AMPK alpha2 downstream of PASK? Our gene-
expression studies revealed that expression of the catalytic
subunit of another glucose-responsive fuel gauge, Prkaa2
(encoding AMPK-alpha2), is upregulated when Pask gene
expression is compromised (Fig. 6). This is an interesting
observation, since AMPK activity has been shown to be
glucose-responsive in pancreatic beta cells [36] and to regulate
insulin release [37, 38]; in addition, we have recently shown
that activation of AMPK in the alpha cell stimulates glucagon
secretion [15]. However, as also observed here, Prkaa2 mRNA
levels are normally much lower (more than tenfold) than
Prkaa1 in purified mouse beta and alpha cells [31], suggesting
that the inappropriate activation of this isoform and an increase
in AMPK activity in the nucleus (from which AMPK alpha1 is
excluded in mature pancreatic endocrine cells) [36] may
impact on the transcription of key genes, including Gcg, to
reprogram the alpha cell. Interestingly, induction of Prkaa2
expression was also observed in E13.5 pancreatic epithelia [33]
in which Pask was silenced (Fig. 6c), indicating that defects
during pancreatic development may contribute to the dysregu-
lation of glucagon release in Pask−/− mice.
PASK may have a role in the pathophysiology of type 2
diabetes The observation that pancreatic islets from
patients with type 2 diabetes display lower PASK mRNA
levels than islets from non-diabetic individuals (Fig. 1b)
suggests that lowered PASK activity may contribute to
decreased insulin release and to enhanced glucagon
secretion in this condition [1]. PASK may therefore
represent a potential therapeutic target, the activation of
which might favourably affect the secretion of both
hormones in patients with type 2 diabetes.
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